Literature DB >> 19843647

The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study.

Camiel Verhamme1, Ivo N van Schaik, Johannes H T M Koelman, Rob J de Haan, Marianne de Visser.   

Abstract

Charcot-Marie-Tooth type 1A is the most prevalent hereditary demyelinating polyneuropathy. The aim of this study was to investigate the natural history of the disease in adults during a 5-year follow-up and to compare the changes over time with those found in normal ageing. In a cohort of 46 adult Charcot-Marie-Tooth type 1A patients, impairments and physical disability were scored at baseline and at 1, 3 and 5 years. Standardized nerve conduction studies and electromyography were performed at baseline and at 5 years. Twenty-six healthy age- and sex-matched controls were evaluated at baseline and at 5 years. Forty-four of 46 Charcot-Marie-Tooth type 1A patients (range 17-69 years) and 26 controls (range 25-65 years) completed the 5-year follow-up. The decrease in muscle strength and in compound muscle action potential amplitudes was similar for patients and controls alike. However, in contrast to the control group, physical disability increased over time in the patient group. In patients, muscle strength and physical disability after 5 years were closely related to these parameters at baseline. None of the other assessed baseline characteristics, i.e. age, gender, compound muscle action potential amplitude and motor nerve conduction velocity, predicted the extent of deterioration of muscle strength or physical disability. In adult Charcot-Marie-Tooth type 1A patients, the decline in axonal function and in muscle strength may reflect, to a considerable extent, a process of normal ageing. The slow increase in physical disability in adulthood may well be explained by decreased reserves and compensatory mechanisms together with progression of skeletal deformations due to muscle weakness.

Entities:  

Mesh:

Year:  2009        PMID: 19843647     DOI: 10.1093/brain/awp251

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  26 in total

Review 1.  A review of genetic counseling for Charcot Marie Tooth disease (CMT).

Authors:  Carly E Siskind; Seema Panchal; Corrine O Smith; Shawna M E Feely; Joline C Dalton; Alice B Schindler; Karen M Krajewski
Journal:  J Genet Couns       Date:  2013-04-21       Impact factor: 2.537

2.  Clinical progression in Charcot-Marie-Tooth disease type 1A duplication: clinico-electrophysiological and MRI longitudinal study of a family.

Authors:  José Berciano; Elena Gallardo; Antonio García; César Ramón; Jon Infante; Onofre Combarros
Journal:  J Neurol       Date:  2010-05-05       Impact factor: 4.849

3.  Nerve conduction velocity in CMT1A: what else can we tell?

Authors:  F Manganelli; C Pisciotta; M M Reilly; S Tozza; A Schenone; G M Fabrizi; T Cavallaro; G Vita; L Padua; F Gemignani; M Laurà; R A C Hughes; A Solari; D Pareyson; L Santoro
Journal:  Eur J Neurol       Date:  2016-07-14       Impact factor: 6.089

4.  Evolution of Charcot-Marie-Tooth disease type 1A duplication: a 2-year clinico-electrophysiological and lower-limb muscle MRI longitudinal study.

Authors:  Ana L Pelayo-Negro; Elena Gallardo; Antonio García; Pascual Sánchez-Juan; Jon Infante; José Berciano
Journal:  J Neurol       Date:  2014-01-22       Impact factor: 4.849

5.  High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial.

Authors:  Richard A Lewis; Michael P McDermott; David N Herrmann; Ahmet Hoke; Lora L Clawson; Carly Siskind; Shawna M E Feely; Lindsey J Miller; Richard J Barohn; Patricia Smith; Elizabeth Luebbe; Xingyao Wu; Michael E Shy
Journal:  JAMA Neurol       Date:  2013-08       Impact factor: 18.302

6.  PMP22 Gene-Associated Neuropathies: Phenotypic Spectrum in a Cohort from India.

Authors:  Madhu Nagappa; Shivani Sharma; Periyasamy Govindaraj; Yasha T Chickabasaviah; Ramesh Siram; Akhilesh Shroti; Monojit Debnath; Sanjib Sinha; Parayil S Bindu; Arun B Taly
Journal:  J Mol Neurosci       Date:  2020-01-28       Impact factor: 3.444

7.  Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial.

Authors:  Camiel Verhamme; Rob J de Haan; Marinus Vermeulen; Frank Baas; Marianne de Visser; Ivo N van Schaik
Journal:  BMC Med       Date:  2009-11-12       Impact factor: 8.775

8.  Improvement of Neuropathy Symptoms With Treatment of Obstructive Sleep Apnea in a Patient With Charcot-Marie-Tooth Disease.

Authors:  Pinar Polat; Huong Pham; Jun Li; Kanika Bagai
Journal:  J Clin Sleep Med       Date:  2018-02-15       Impact factor: 4.062

9.  Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.

Authors:  Sinéad M Murphy; David N Herrmann; Michael P McDermott; Steven S Scherer; Michael E Shy; Mary M Reilly; Davide Pareyson
Journal:  J Peripher Nerv Syst       Date:  2011-09       Impact factor: 3.494

Review 10.  Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.

Authors:  Burkhard Gess; Jonathan Baets; Peter De Jonghe; Mary M Reilly; Davide Pareyson; Peter Young
Journal:  Cochrane Database Syst Rev       Date:  2015-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.